Janice Charette · Chief Trade Negotiator, Global Affairs Canada (GAC)
Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.Read more
Mark Wiseman · Ambassador of Canada to the United States, Global Affairs Canada (GAC)
Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policyRead more
Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
Julie Harb · Policy Advisor, Prime Minister's Office (PMO)
Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policyRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.
Martin Moen · Associate Asst Dep. Minister of International Trade and Chair of the Canada/U.S. Trade and Economic Task Force, Global Affairs Canada (GAC)
Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Fatouma Bah · Policy Advisor, Health Canada (HC)
Supriya Sharma · Acting ADM, Health, Health Canada (HC)
Scott Lohnes · Senior Advisor, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.Read more
Mélanie Joly · Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policyRead more
Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement
Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.
Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
and 6 moreShow fewer
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.Read more
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
and 6 moreShow fewer
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Jibril Hussein · Senior Policy Advisor, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.Read more
Arianne Reza · Associate Deputy Minister, Public Services and Procurement Canada (PSPC)
Joelle Paquette · Associate Assistant Deputy Minister, Public Services and Procurement Canada (PSPC)
Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.Read more
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategyRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
Tim Krupa · Director of Policy, Prime Minister's Office (PMO)
Brandan Rowe · Chief of Staff, Privy Council Office (PCO)
Martin Moen · Associate Asst Dep. Minister of International Trade and Chair of the Canada/U.S. Trade and Economic Task Force, Global Affairs Canada (GAC)
Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade AgreementRead more
Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.
Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
and 3 moreShow fewer
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.Read more
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.Read more
Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy
Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods
Free trade agreements as they relate to the biopharmaceutical industry.
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policyRead more
Free trade agreements as they relate to the biopharmaceutical industry.
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
and 5 moreShow fewer
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Deputy Chief of Staff & Director of Policy, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policyRead more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB).
Free trade agreements as they relate to the biopharmaceutical industry.
Martin Moen · Associate Assistant Deputy Minister of the International Trade Branch, Global Affairs Canada (GAC)
Justine Frame · Special Assistant - Policy, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Sharlene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States.Read more
Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy
Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement
Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy
Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.
Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods
Kabisan Thanendran · Policy Advisor, Public Services and Procurement Canada (PSPC)
Chanel Sterie · Senior Policy Advisor, Public Services and Procurement Canada (PSPC)
Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.Read more
Paul Moen · Chief of Staff to the Minister, Innovation, Science and Economic Development Canada (ISED)
Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policyRead more
Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.
Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement
Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy
Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policyRead more
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategyRead more
Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy
Ritu Banerjee · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade AgreementRead more
Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.
Advocacy on the role of the Health Emergency Readiness Canada (HERC) Agency
Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
Paul Hebert · President, Canadian Institutes of Health Research (CIHR)
Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.Read more
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy
Ian Foucher · Chief of Staff to the Minister, Finance Canada (FIN)
Matthew O'Connell · Deputy Director of Policy, Office of the Minister, Finance Canada (FIN)
Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance.Read more
Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods
Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement
Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
David McFarlane · Director of Policy, Innovation, Science and Economic Development Canada (ISED)
Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade AgreementRead more
Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods
Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance.
Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.